Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00110357
Status:
COMPLETED
Last Update Posted:
2015-12-24
First Post:
2005-05-06
Brief Title:
Study of Erbitux Cetuximab in Pediatric Patients With Refractory Solid Tumors
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Phase I Study of Erbitux Cetuximab in Pediatric Patients With Refractory Solid Tumors
Status:
COMPLETED
Status Verified Date:
2015-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical research study is to establish the maximum tolerated dose and recommended Phase II dose of Erbitux in combination with Irinotecan in pediatric and adolescent patients with refractory solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None